Try our beta test site
Text Size
42 studies found for:    "GW Pharmaceuticals Ltd." [Exact]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Withdrawn A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
Condition: Advanced Cancer
Intervention: Drug: Sativex
2 Withdrawn A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
Conditions: Renal Insufficiency;   Kidney Disease
Intervention: Drug: Sativex
3 Completed An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.
Condition: Healthy Subjects
Interventions: Drug: Sativex® (Treatment A);   Drug: Sativex® and fluconazole concomitantly (Treatment B)
4 Terminated A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects
Condition: To Provide Further Information About the Potential Need for Sativex Dose Adjustments in Patient Populations.
Intervention: Drug: Sativex
5 Unknown † An Observational Post-Marketing Safety Registry of Sativex®
Conditions: Multiple Sclerosis;   Diabetes;   Cancer;   Neuropathic Pain
Intervention: Drug: Sativex®
6 Terminated A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Sativex
7 Completed
Has Results 		A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
Conditions: Multiple Sclerosis;   Spasticity
Interventions: Drug: Sativex;   Drug: Placebo
8 Completed Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
Condition: Hepatic Impairment
Intervention: Drug: Sativex
9 Completed
Has Results 		An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: GW-1000-02
10 Completed
Has Results 		An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Interventions: Drug: GW-1000-02;   Drug: Placebo
11 Completed
Has Results 		A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Drug: GW-1000-02
12 Completed
Has Results 		A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury
Condition: Pain
Interventions: Drug: GW-1000-02;   Drug: Placebo
13 Completed
Has Results 		A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain
Condition: Pain
Interventions: Drug: GW-1000-02;   Drug: GW-2000-02;   Drug: Placebo
14 Completed
Has Results 		A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
Conditions: Pain;   Multiple Sclerosis
Interventions: Drug: GW-1000-02;   Drug: Placebo
15 Completed
Has Results 		A Study of the Long-term Safety of Sativex Use
Conditions: Multiple Sclerosis;   Spasticity;   Pain
Intervention: Drug: GW-1000-02
16 Completed
Has Results 		A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
Conditions: Multiple Sclerosis;   Neuropathic Pain
Interventions: Drug: Placebo;   Drug: Sativex
17 Completed
Has Results 		A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sativex;   Drug: Placebo
18 Completed A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Conditions: Pain;   Advanced Cancer
Interventions: Drug: Sativex®;   Drug: Placebo (product code GA0034)
19 Completed Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Conditions: Pain;   Advanced Cancer
Interventions: Drug: Sativex®;   Drug: Placebo (GA-0034)
20 Completed Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Conditions: Pain;   Advanced Cancer
Intervention: Drug: Sativex®
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Study has passed its completion date and status has not been verified in more than two years.